Previous 10 | Next 10 |
MADISON, Wis. and ROCHESTER, Minn. , Dec. 4, 2019 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS) today announced Dr. David Ahlquist , co-inventor of Cologuard ® and emeritus professor of medicine in the Division of Gastroenterology and Hepatology at Mayo Clinic, has bee...
Introduction Over the past year, there has been a lot of coverage on Seeking Alpha about Exact Sciences ( EXAS ) and Guardant Health ( GH ), two companies playing in the emerging precision oncology space . This article focuses on comparing the two companies which are both chasing the same m...
MADISON, Wis. , Nov. 26, 2019 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that company management will be participating in the following investor conference. Evercore ISI HealthCONx, Boston Fireside chat on December 4, 2019 , at 2:45 p.m. EST ...
Usually, Once A Pattern Is Well Recognized It Stops Working I am hoping that I caught one before it really emerges. If we have, then we should generate good alpha. I believe I see the logic in it as well, just by examining my own "gut" over the course of the last few weeks. As we break i...
This month, Exact Sciences (NASDAQ: EXAS) finalized its purchase of Genomic Health, creating a formidable player in the realm of cancer diagnostics. Exact shelled out approximately $1.06 billion in cash and issued roughly 17.4 million shares to Genomic Health shareholders. Currently valued ...
Some early investors have gotten rich from the genomics revolution. The stocks of two of the top companies in the genomics arena, Exact Sciences (NASDAQ: EXAS) and Illumina (NASDAQ: ILMN) , have delivered returns of more than 2,800% and 780%, respectively, over the last 10 years. Both of...
Agilent (NYSE: A ) initiated with Hold rating and $85 (11% upside) price target at Stifel. More news on: Agilent Technologies, Inc., Avantor, Inc., Bio-Techne Corporation, Healthcare stocks news, Stocks on the move, , Read more ...
Combined company joins two leading brands in cancer diagnostics, Cologuard® and Oncotype DX®, providing a strong platform for continued growth MADISON, Wisconsin , Nov. 8, 2019 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS) today announced that it has completed its...
BOSTON , Nov. 8, 2019 /PRNewswire/ -- (NASDAQ: EXAS) – A new study of 443 patients by Exact Sciences Corp. and its collaborators demonstrated 80% sensitivity at 90% specificity with a novel combination of six blood-based biomarkers for the most common type of liver canc...
The following slide deck was published by Exact Sciences Corporation in conjunction with this Read more ...
News, Short Squeeze, Breakout and More Instantly...
Exact Sciences Corporation Company Name:
EXAS Stock Symbol:
NASDAQ Market:
Exact Sciences Corporation Website:
Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conference and invited investors to participate by webcast. BofA Securities Health Care Conference, Las Vegas Firesid...
2024-05-01 02:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-04-15 11:30:02 ET William Blair analyst issues OUTPERFORM recommendation for EXAS on April 15, 2024 10:21AM ET. The previous analyst recommendation was Outperform. EXAS was trading at $68.965 at issue of the analyst recommendation. The overall analyst consensus : BU...